IQ EQ FUND MANAGEMENT IRELAND Ltd Purchases 32,555 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

IQ EQ FUND MANAGEMENT IRELAND Ltd grew its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 160.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 52,787 shares of the company's stock after acquiring an additional 32,555 shares during the quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd's holdings in 10x Genomics were worth $758,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in TXG. Atria Wealth Solutions Inc. boosted its stake in shares of 10x Genomics by 9.6% in the 4th quarter. Atria Wealth Solutions Inc. now owns 10,788 shares of the company's stock valued at $155,000 after purchasing an additional 943 shares during the last quarter. Blue Trust Inc. grew its holdings in 10x Genomics by 73.1% during the 4th quarter. Blue Trust Inc. now owns 3,075 shares of the company's stock worth $44,000 after acquiring an additional 1,299 shares during the period. Sound Income Strategies LLC lifted its stake in shares of 10x Genomics by 65.2% in the 4th quarter. Sound Income Strategies LLC now owns 3,370 shares of the company's stock valued at $48,000 after purchasing an additional 1,330 shares during the period. Signaturefd LLC boosted its position in shares of 10x Genomics by 424.6% during the 4th quarter. Signaturefd LLC now owns 1,794 shares of the company's stock valued at $26,000 after purchasing an additional 1,452 shares in the last quarter. Finally, KBC Group NV lifted its stake in 10x Genomics by 57.3% in the fourth quarter. KBC Group NV now owns 5,072 shares of the company's stock valued at $73,000 after buying an additional 1,847 shares during the period. Institutional investors own 84.68% of the company's stock.

Remove Ads

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, Director Alan Mateo purchased 40,000 shares of the stock in a transaction on Friday, February 21st. The shares were purchased at an average price of $11.14 per share, with a total value of $445,600.00. Following the acquisition, the director now directly owns 61,691 shares in the company, valued at approximately $687,237.74. The trade was a 184.41 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Serge Saxonov sold 5,092 shares of the business's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $56,368.44. Following the transaction, the chief executive officer now directly owns 879,482 shares of the company's stock, valued at $9,735,865.74. The trade was a 0.58 % decrease in their position. The disclosure for this sale can be found here. Insiders own 10.03% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on TXG shares. Leerink Partnrs cut 10x Genomics from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 13th. Weiss Ratings reiterated a "sell (e+)" rating on shares of 10x Genomics in a report on Saturday, March 22nd. Leerink Partners cut shares of 10x Genomics from an "outperform" rating to a "market perform" rating and cut their price target for the stock from $25.00 to $12.00 in a report on Thursday, February 13th. Citigroup dropped their target price on shares of 10x Genomics from $20.00 to $15.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. Finally, Barclays decreased their target price on 10x Genomics from $19.00 to $18.00 and set an "overweight" rating for the company in a research report on Monday, February 10th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, 10x Genomics currently has an average rating of "Hold" and an average target price of $20.21.

10x Genomics Stock Down 4.7 %

TXG traded down $0.43 during trading on Monday, reaching $8.73. 2,397,540 shares of the company were exchanged, compared to its average volume of 2,077,107. 10x Genomics, Inc. has a 12-month low of $8.68 and a 12-month high of $37.86. The company's 50-day moving average is $12.12 and its two-hundred day moving average is $15.04. The company has a market cap of $1.07 billion, a price-to-earnings ratio of -5.74 and a beta of 1.93.

10x Genomics (NASDAQ:TXG - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. Equities analysts forecast that 10x Genomics, Inc. will post -1.43 earnings per share for the current year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.